The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 ...

Novavax experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board and the ...

NEW YORK — President Donald Trump has launched tariff wars with nearly all of America’s trading partners. And there’s no end in sight. A number of sweeping new taxes on goods from other ...

Just last week, the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health ...